Mold-Tek Packaging raises FY27 EBITDA per kg target to ₹44-45
Mold-Tek Packaging delivered strong Q1FY27 results with net profit rising 14.19% to ₹25.57 crore and revenue crossing ₹300 crore. Record EBITDA per kg of ₹46.68 was achieved through Hyderabad unit consolidation and pharma segment growth. Management raised FY27 EBITDA per kg guidance to ₹44-45 and outlined plans for medical device expansion.
*this image is generated using AI for illustrative purposes only.
Mold-Tek Packaging revised its full-year EBITDA per kilogram target upward to ₹44-45 for FY27, up from the initial guidance of ₹42-43, following a record Q1FY27 performance. The company reported a net profit of ₹25.57 crore, a 14.19% year-on-year increase, while revenue from operations surged 24.90% to ₹300.45 crore. This financial strength was underpinned by a historic high in EBITDA per kilogram at ₹46.68, driven primarily by the strategic consolidation of five Hyderabad manufacturing units into two facilities and robust growth in high-margin pharma and Food & FMCG segments.
Chairman and Managing Director J Lakshmana Rao emphasized that the improved profitability stems from long-term structural efficiencies rather than temporary factors. The consolidation reduced overheads, inter-unit transfers, and rejection rates, allowing the company to maintain margin stability despite global geopolitical uncertainties affecting raw material prices. While volume growth was moderate at 6.25% to 12,089 MT, the shift towards higher-value products offset lower volumes in traditional segments like lubricants.
Segment Performance and Mix Shift
The pharma packaging vertical emerged as the primary growth engine, with sales volume increasing by 38.75%. Although pharma currently contributes only 3.5% of overall sales value, management projects a 40-50% compound annual growth rate (CAGR) over the next three to four years. Food & FMCG packs also performed strongly, registering a 26.20% volume growth supported by doubled production capacity at the Panipat facility.
Conversely, the Lube Packs segment faced significant headwinds, contracting by 17% due to base oil supply disruptions linked to geopolitical tensions in the Middle East. J Lakshmana Rao noted that this decline directly impacted overall volume growth; without the lube dip, volume growth would have been closer to 9-9.5%. Paints packs saw a steady 10.82% volume growth, with management targeting 10-15% growth for the full year as In-Mold Labeling (IML) adoption accelerates among major clients like Asian Paints.
| Segment: | Volume Growth (YoY): | Key Drivers/Challenges: |
|---|---|---|
| Pharma: | +38.75%: | New client acquisition, lightweight containers |
| Food & FMCG: | +26.20%: | Capacity expansion at Panipat, new customers |
| Paints: | +10.82%: | IML adoption, existing client retention |
| Lube Packs: | -17.00%: | Base oil unavailability due to geopolitical issues |
Operational Efficiencies and Cost Management
The divergence between revenue growth (24.90%) and volume growth (6.25%) highlights the impact of raw material inflation and product mix shifts. Raw material costs rose from an average of ₹107 per kg in Q4FY26 to ₹130 per kg in Q1FY27. Mold-Tek successfully passed these increases to clients within a month, preserving margins. Chairman J Lakshmana Rao attributed approximately ₹3 per kg of the EBITDA improvement to higher realization from pharma and FMCG, and another ₹3 per kg to consolidation-driven efficiencies.
Working capital requirements increased, with current working capital rising to ₹125 crore from ₹112 crore at the end of March 2026. This led to a 20% quarter-on-quarter rise in finance costs, which management clarified was due to higher inventory carrying costs rather than increased term debt. The company maintains a standard inventory holding period of three weeks to one month.
Future Outlook and New Ventures
Management outlined a CapEx plan of ₹90 crore for FY27, with ₹25-30 crore allocated specifically for pharma expansion. The company aims for 10-12% annual capacity additions across its Cheyyar, Panipat, and Mahad units to improve utilization rates from 75% to 80%.
Beyond core packaging, Mold-Tek is exploring high-value medical devices, including dosing pens and ophthalmic products. Trial molds for ophthalmic products are complete, with commercial production expected by early next year. For dosing pens, the company is pursuing IP partnerships to reduce development time from three years to one, with a minimum initial investment of ₹25-30 crore required for plant setup. Semiconductor trays remain a longer-term opportunity contingent on technology partnerships.
What the Numbers Show
The record EBITDA per kg of ₹46.68 demonstrates that operational restructuring has created a durable cost advantage that outpaces input cost volatility. While the lube segment’s decline masked underlying demand strength, the rapid scaling of pharma and FMCG suggests a successful transition toward higher-margin, value-added products. The ability to pass on raw material inflation immediately indicates strong pricing power and client stickiness, positioning the company to sustain elevated profitability even if volume growth remains moderate.
Historical Stock Returns for Mold-Tek Packaging
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.89% | +0.13% | -0.94% | +22.79% | -12.61% | +44.49% |
How might the geopolitical disruptions affecting base oil supply evolve, and what contingency strategies does Mold-Tek have to mitigate further declines in the Lube Packs segment?
Given the projected 40-50% CAGR in pharma packaging, what specific regulatory or client acquisition hurdles could delay the segment from becoming a more significant revenue contributor beyond its current 3.5% share?
Will the company's strategy to pass on raw material inflation within a month remain sustainable if global commodity prices continue to rise, or does this risk impacting long-term client relationships?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
